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Abstract
Background & aims: Nutritional supplementation with polyunsaturated fatty acids is important in preterm infants
neurodevelopment, but it is not known if the omega-6/omega-3 ratio affects this process. This study was designed to
determine the effects of a balanced contribution of arachidonic acid in very preterm newborns fed with formula milk.
Methods: This was a randomized trial, in which newborns <1500 g and/or <32 weeks gestational age were assigned
to one of two groups, based on the milk formula they would receive during the first year of life. Initially, 60 newborns
entered the study, but ultimately, group A was composed of 24 newborns, who were given formula milk with an ω-6/
ω-3 ratio of 2/1, and Group B was composed of 21 newborns, given formula milk with an ω-6/ω-3 ratio of 1/1. The
infants were followed up for two years: growth, visual-evoked potentials, brainstem auditory-evoked potentials, and
plasma fatty acids were periodically measured, and psychomotor development was assessed using the Brunet Lézine
scale at 24 months corrected age. A control group, for comparison of Brunet Lézine score, was made up of 25
newborns from the SEN1500 project, who were fed exclusively with breast milk.
Results: At 12 months, arachidonic acid values were significantly higher in group A than in group B (6.95 ± 1.55 % vs.
4.55 ± 0.78 %), as were polyunsaturated fatty acids (41.02 ± 2.09 % vs. 38.08 ± 2.32 %) achieved a higher average. Group
A achieved a higher average Brunet Lézine score at 24 months than group B (99.9 ± 9 vs. 90.8 ± 11, p =0.028). The
Brunet Lézine results from group A were compared with the control group results, with very similar scores registered
between the two groups (99.9 ± 9 vs. 100.5 ± 7). There were no significant differences in growth or evoked potentials
between the two formula groups.
Conclusions: Very preterm infants who received formula with an ω-6/ω-3 ratio of 2/1 had higher blood levels of
essential fatty acids during the first year of life, and better psychomotor development, compared with very preterm
newborns who consumed formula with an ω-6/ω-3 of 1/1. Therefore, formula milk with an arachidonic acid quantity
double that of docosahexaenoic acid should be considered for feeding very preterm infants.
Trial registration: ClinicalTrials.gov Identifier NCT02503020.
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Background
Long-chain polyunsaturated fatty acids (LCPUFAs), ara-
chidonic acid (AA omega-6; 20:4ω-6), and docosahexae-
noic acid (DHA omega-3; 22:6ω-3), are required for the
formation of non-myelinated cell membranes in the cen-
tral nervous system, including in the retina [1, 2], hence
their great importance in appropriate visual and cogni-
tive development. LCPUFAs are transferred from mother
to foetus mainly during the last trimester of pregnancy
[2, 3]. At that time, and in the early neonatal period, suf-
ficient levels of DHA and AA are required for the rapid
synthesis of brain tissue, cellular differentiation, and ac-
tive synaptogenesis [4, 5]. In premature infants, this cru-
cial supply is interrupted and they exclusively depend on
breast milk and other exogenous sources [5]. Moreover,
very-low-birth-weight (VLBW) and very preterm infants
are particularly vulnerable to LCPUFAs deficiency, given
the virtual absence of adipose tissue at birth, the poten-
tial immaturity of fatty acid elongation/desaturation
pathways, and inadequate fatty acid intake from formula
milk if not breast fed [6].
Arachidonic acid is the most abundant ω-6 LCPUFA,
and DHA is the most biologically important ω-3
LCPUFA in breast milk [7]. The ratio of AA to DHA in
human milk is usually 1.5-2/1, but the variability is high,
and the ratio is primarily determined by the habitual diet
of the region or country [8, 9]. The nutritional require-
ments for LCPUFAs in preterm newborns are not clearly
established, because optimal LCPUFA blood levels and
accretion rate are not well known [10, 11].
It has been reported that newborns fed with DHA- and
AA-supplemented formula had higher Bayley mental and
psychomotor development scores, with no increase in
morbidity or adverse events [12]. Likewise, other studies
in term and preterm infants considered formulas contain-
ing DHA to be more appropriate, because of the frequent
deficiency of DHA in the first days of life in VLBW infants
[13, 14]. However, it must be remembered that AA is also
a key component of cell membranes and is one of the
most abundant fatty acids in the brain: it helps maintain
hippocampal cell membrane fluidity [15], protects the
brain from oxidative stress by activating peroxisome
proliferator-activated receptor gamma [16], and activates
syntaxin-3 (STX-3), a protein involved in the growth and
repair of neurons [17]. In one study, term infants who
were given supplemental AA showed significant improve-
ments in intelligence, as measured with the Mental Devel-
opment Index [18]. The dietary balance between ω-6 and
ω-3 and their LCPUFA metabolites is likely to be import-
ant in humans of all ages, but perhaps even more so in
preterm infants [19, 20].
Almost all preterm infant formulas contain AA sup-
plementation. However, the formulas often contain an
ω-6 to ω-3 ratio of 1/1. This study aimed to clarify the
importance of higher formula AA values and establish
the preferred omega-6/omega-3 ratio for supplementa-
tion of breast milk, by assessing anthropometric, visual,
auditory, and psychomotor development in very preterm
infants receiving diets supplemented with different AA/
DHA ratios (1/1 vs. 2/1).
Patients and methods
Study design
This prospective randomized controlled double-blind trial
was conducted to study nutritional supplementation in
preterm infants <1500 g and/or between 25–32 weeks ges-
tational age (GA) who were born at the University Clinical
Hospital of Santiago de Compostela (CHUS). The infants
were enrolled for a period of 14 months (from July 2011 to
August 2012) and followed up from birth until 2 years of
age. Milk formulas were provided either as adjunct to in-
sufficient breast milk quantity or as full formula feeding.
Breastfeeding was actively encouraged. Patients were ran-
domly assigned to one of the two formula groups, accord-
ing to the type of formula they were to receive. The group
A formula was supplemented with AA and DHA with an
ω-6/ω-3 ratio of 2/1. The group B formula was supple-
mented with AA and DHA with an ω-6/ω-3 ratio of 1/1.
The primary outcome was psychomotor development,
assessed with the Brunet Lézine scale at 2 years of age
(Early Care Unit, CHUS). The secondary outcomes were
plasma levels of fatty acids at 3 months, 6 months, and
12 months (Metabolic Unit, Cruces Hospital, Bilbao); vis-
ual- and auditory-evoked potentials at 6 and 12 months of
age (Neurophysiology Unit, CHUS); and anthropometric
measurements (weight, length, and head circumfer-
ence) at 3, 6, 9, 12, 18, and 24 months of age (Neonatology
Unit CHUS).
The Brunet Lézine assessment results from the 2 sam-
ple groups were compared with the results from 25 pre-
term infants (<1500 g) from the same hospital (CHUS)
who were fed exclusively with human milk. Information
was used from the <1500 g preterm data registry of the
Spanish Society of Neonatology (SEN 1500). This program
includes 62 hospitals and centres throughout Spain, CHUS
being one of them. The 25 most recently-born preterm in-
fants (<1500 g) who were exclusively breast-fed were
chosen. There was no human milk bank available, there-
fore all infants were fed with their own mother's milk.
Power calculation and randomization
The primary outcome of the study was psychomotor de-
velopment. Differences in the Brunet Lezine score were
expected; therefore, the sample size was calculated on
this parameter using Brunet Lezine score results from
the SEN 1500 study over 9 years (from 2003 to 2011).
The absolute effect size was estimated for comparison
between formula- and human milk-fed children: it was
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7.2 points. The sample size was 30 infants in each group,
achieving an observed power of 80 %. The double-blind
randomized allocation of infants to a study formula was
stratified for gender, and a block size of four was applied.
The researcher that generated the random allocation
sequence was not the same researcher that enrolled
participants and assigned participants to interventions.
Participants and investigators were blinded to formula
allocation until all data analysis had been performed.
Study population
During the data collection period, 3357 infants were
born in our Hospital, of which 61 weighed <1500 g and/
or were 25–32 weeks GA. One child was excluded dur-
ing the first week due to a severe malformation; all other
parents gave consent to participate in the study (30 in-
fants in each group). Patients in the following situations
were excluded: preterm infants with severe malformations,
preterm infants with severe intraventricular haemorrhage
or periventricular leukomalacia (more than grade 2), and
neonates who did not need supplementary milk nutrition,
i.e. breast-fed only children.
Sixty preterm infants entered the study in the first
week of age. One died at 2 months, and communication
was lost with two more: one at 3 months and the other
at 6 months of age. Three preterm infants were excluded
during their first two months because of severe intraven-
tricular haemorrhage, and nine children converted to ex-
clusive breastfeeding during the first six months. From
6 months until the end of the study, 45 children were in-
cluded and followed up: 24 infants in group A and 21 in
group B.
Ethical statement
The study was approved by the Galician Research Ethics
Committee, Spain. Written informed consent was ob-
tained from all parents, after the experimental protocol
had been explained to them in detail. The study was reg-
istered at ClinicalTrials.gov (NCT02503020).
Dietary intervention
Breastfeeding was encouraged in all preterm infants. Ne-
onates who could not meet more than half their milk re-
quirements from their mothers’ milk alone at the end of
the first week of age were included in the study. Infants
in group A received milk formula for preterm infants
containing a fixed amount of ω-3 (DHA) lipids (0.33 %)
with an ω-6/ω-3 ratio of 2/1. Infants in group B received
formula for preterm infants containing a similar quantity
and quality of proteins, carbohydrates, lipids, vitamins,
and micronutrients as group A, and a fixed amount of
ω-3 lipids (0.37 %) but with an ω-6/ω-3 ratio of 1/1. It
should be noted that neither of the formulas used con-
tained other sources of ω-6 and ω-3 besides AA and
DHA, therefore when this study refers to the ω-6/ω-3
ratio, it is equivalent to the AA/DHA ratio. Whilst in
hospital, the two groups received similar quantities of
fluids and calories (almost 160 ml/kg/day of fluids, and
120 kcal/kg/day), and a breast milk fortifier that did not
contain lipids. At 3 and 6 months of corrected age, the
milk type was changed according to nutritional require-
ments, but the same ω-6/ω-3 ratio was maintained in
each group. Parents began adding complementary foods
at five months of life. They kept a daily nutrition diary,
and the omega-6/omega-3 ratio in foods was strictly
controlled so that the two groups received similar
amounts of both omega-6 and omega-3 apart from the
formula. The families of all children in both groups were
given the same recommendations and encouraged to
introduce complementary foods together with milk.
Table 1 presents the main contents of the formulas used
in this study [21].
Methods
For fatty acid analysis, blood samples were collected
from study children at 1 week of age, then at 3, 6, and
12 months. The samples were collected in tubes with
anticoagulant (EDTA). After immediate centrifugation
the plasma was separated and stored at −80 °C until ana-
lysis. When all samples had been received in the labora-
tory, plasma total fatty acids were trans-methylated as
per the method described by Lepage and Roy [22]. Using
tridecanoic acid as the internal standard, the fatty acid
methyl esters were separated and quantified on an Agi-
lent Technologies 7890A gas chromatograph using a
flame ionization detector on a capillary column SP-2380
(Supelco, Bellefonte, PA, USA). Fatty acids were identi-
fied by comparison with commercial standards from Nu-
Chek (Elysian, MN, USA) and Sigma (Madrid, Spain).
Each fatty acid was quantified using electronic integration
in the offline Chem Station. Nutritional content was cal-
culated using a dietary calculation computer programme
(www.odimet.es).
Anthropometric assessment was performed by the
same personnel and with the same devices for both
groups. For weight, a special balance was used (Seca),
which had two programs: one with an expected error of
3 g and minimum and maximum limits of 40 g – 6000 g,
respectively, (used until 3 months of age) and the other
program with an expected error of 5 g and minimum and
maximum limits of 100 g – 15 000 g, respectively, (used
for infants older than 3 months). Length was measured
using a special sliding infant measuring table (counter
recording) with an expected error of 2 mm and a mini-
mum and maximum of 20 cm and 100 cm, respectively
(Holtain). Head circumference was determined using a
non-stretchable measuring tape, measuring the perimeter
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at the level of the occipital prominence at the back and
the mid forehead at the front.
Evoked potentials were performed using the same
technique and device in both groups (Nicolet Viking IV
NT), and the results were evaluated by the same trained
personnel. Psychomotor development was assessed using
the Brunet Lézine Scale. The Brunet Lezine scale pro-
vides an objective evaluation of a child’s maturation level
in four areas: motor, coordination, language, and social
[23]; an overall score ≥85 is considered normal.
Study of other risk factors
It was important to establish if there were differences be-
tween group A and group B in terms of risk factors that
could affect mental development. Therefore, sex, gesta-
tional age (assessed by prenatal echo), birth weight,
APGAR, use of surfactant, sepsis, need for mechanical ven-
tilation, use of FiO2 > 30 %, presence of intracranial haem-
orrhage, administration of ibuprofen for patent ductus
arteriosus, and presence of bronchopulmonary dysplasia
were assessed in all children who entered the study. Finally,
parents were asked if they worked, and if they had a uni-
versity degree. The two groups were compared, and no sig-
nificant differences were found between them (Table 2).
Statistical analysis
All statistical calculations were performed with SPSS
(SPSS, v.20.0, Chicago, Illinois, USA). Normality of data
Table 2 Comparison of risk factors in children between the three groups
Some risk factors ω-6/ω-3 = 2 ω-6/ω-3 = 1 Control group p value
Group A Group B
n = 24 n = 21 n = 25
n (rate) n (rate) n (rate)
Male 12 (50 %) 11 (52 %) 12 (48 %) ns
Gestation age <30 weeks 7 (29 %) 7 (33 %) 8 (32 %) ns
Weight at birth < 1000gm 5 (21 %) 4 (19 %) 5 (20 %) ns
APGAR at 5 min < 9 5 (21 %) 4 (19 %) 4 (25 %) ns
APGAR at 10 min <9 2 (8 %) 2 (10 %) 3 (12 %) ns
Need of surfactant 8 (33 %) 8 (38 %) 8 (32 %) ns
Sepsisa 4 (17 %) 4 (19 %) 5 (20 %) ns
Mechanical ventilation 9 (38 %) 6 (29 %) 8 (32 %) ns
Need of Fio2 > 30 % 9 (38 %) 7 (33 %) 6 (24 %) ns
Intra cranial hemorrhage (grade I or II) 3 (13 %) 3 (14 %) 4 (16 %) ns
Need of ibuprofen 7 (29 %) 7 (33 %) 7 (28 %) ns
Broncho pulmonary dysplasiab 2 (8 %) 1 (5 %) 1 (4 %) ns
Both parents do not have job 2 (8 %) 1 (5 %) 2 (8 %) ns
Both parents do not have university degree 13 (54 %) 12 (57 %) 12 (48 %) ns
Data are presented as number (percentage), significant differences between groups (p < 0.05, Chi-square test)
aPreterm infants who had positive blood culture with appropriate clinical suspected status
bPreterm infants who had oxygen requirement either at 28 postnatal days or 36 weeks postmenstrual age
Table 1 Total proteins, lipids, and carbohydrate per 100 ml of formula used
Compositions of 100 ml of used formulas Total proteins g/100 ml Total lipids g/100 ml Total carbohydrates g/100 ml
Group A formula (ω-6/ ω-3 = 2) Preterm formula (16 %) 2.35 4 8.64
First 6 months formula (13 %) 1.43 3.77 7.15
6-12 months formula (13 %) 1.65 2.92 7.67
Group B formula (ω-6/ ω-3 = 1) Preterm formula (16 %) 2.27 4.22 8.51
First 6 months formula (13 %) 1.52 3.57 7.67
6-12 months formula (13 %) 1.61 3.09 7.52
Human milk (22) Born <29 weeks GA 2.2 4.4 7.6
Born 32–33 weeks GA 1.9 4.8 7.5
p value ns ns ns
[22], Bauer et al. [21]; 13 % and 16 %, the concentration of the formula (g/100 cc). Significant differences between groups (p <0.05, Kruskal-Wallis test)
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was analyzed with the Shapiro–Wilk test. A p value < 0.05
was considered statistically significant (two-tailed test),
with 95 % confidence interval. Multiple testing corrections
were performed using Bonferroni correction. Qualitative
variables were compared between groups using a chi-
square test. To evaluate Brunet Lezine score, Wilcoxon
test was performed between each pair of groups (A
and B, A and control, and B and control). For plasma
fatty acid values and anthropometric measurements,
quantitative variables were compared between groups
using Wilcoxon test.
Results
Sixty-one infants were recruited (Fig. 1), and 60 infants
were randomly assigned to one of the two study formu-
las. Forty-five infants were followed up until 24 months
of age.
During the first month of life, 54 of group A and 48 %
of group B were fed on breast milk supported with one
of the formulas. At 3 months of chronological age, 79 of
group A and 76 % of group B were fed exclusively on
formula, and at 6 months, 92 of group A and 86 % of
group B were fed exclusively on formula. The percentage
of feeds provided by breast milk in all mixed-fed infants
was less than 40 % of total milk {Group A, mean 21 %,
(range 10 % to 35 %). Group B, mean 26 %, (range 15 %
to 40 %)}. There were no statistically significant differ-
ences between the two groups.
Psychomotor development
At 24 months’ corrected age, the three groups were
assessed using the Brunet Lézine scale. The proportion
of preterm infants with a Brunet Lézine score greater
than or equal to 85 was studied and compared, as was
the mean score of each group, and a significant differ-
ence was noted (Table 3). Each group was then com-
pared with the two other groups separately. There was a
significant difference between group A and group B:
Fig. 1 Dietary intervention and follow-up of children during the first two years of life. CA, corerected age; IVH, intraventricular hemorrhage
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only one child had a score less than 85 in group A, com-
pared with six children in group B. There was also a
significant difference in the average scores of groups A
and B. The Brunet Lézine results of the control group,
who were exclusively breast-fed, were compared with both
formula groups: group A and the control group had a
similar proportion of children with a score less than 85
and similar average scores. However, group B had worse
results than the control group for both proportion of chil-
dren with a score less than 85 and average score.
Lipid profile
Some samples were not taken during follow-up due to
parental refusal (one at 1 week, five at 3 and 6 months
each, and three at 12 months of age). Children from
group A had the following results compared with group
B (Table 4): significantly higher total levels of ω-6, AA,
and PUFA at 6 and 12 months corrected age; signifi-
cantly higher levels of DHA and ω-3 at 6 months; and
similar plasma ω-6/ω-3 ratio at 3, 6, and 12 months of
age. There were no significant differences in docosapen-
taenoic acid (C22:5ω3), eicosapentaenoic acid (C20:5ω3),
or linoleic acid (C18:2ω6) between the two groups at 6
or 12 months.
Anthropometric measurement and evoked potentials
There were no significant differences between the two
groups for the variables of weight, length, or head cir-
cumference, during the first two years of life. Likewise,
there were no statistically significant differences in the
results of visual- and brainstem auditory-evoked poten-
tials at 6 and 12 months corrected age (Table 5).
Discussion and conclusions
This trial studied very preterm infants who received sup-
plementary formulas with different AA/DHA ratios (group
A, 2/1 and group B, 1/1). Group A had significantly higher
plasma values of arachidonic acid and polyunsaturated
fatty acids than group B. Group A also achieved a higher
average Brunet Lézine score at 24 months than group B.
Regarding Brunet Lézine score at 24 months, there
was a statistically significant difference between the two
groups: in group A (ω-6/ω-3 = 2/1), only 4.2 % had a
score less than 85. Also, group A had a higher mean
score than group B. This could have been due to the
higher quantity of ω-6 or PUFAs that group A were fed,
as well as the higher plasma levels of ω-6 and PUFAs in
group A compared with group B. To explain these re-
sults, it must be remembered that AA is a key compo-
nent of cell membranes, serves as a precursor to
prostaglandin formation, and is clearly involved in the
signalling systems of the brain [15]. Whilst it is acknowl-
edged that maternal milk is the ideal milk and generally
contains a higher concentration of AA than formula
milk [8, 28, 29], the amount of AA needed by preterm
infants to maintain ideal brain development is not clear,
and more studies and further discussion are required.
To clarify the results of this study, we reiterate that the
two formula groups were randomly assigned, then ob-
served and followed closely during the first two years of
life. From the beginning of the study, the two groups
had similar gestational ages, weights at birth, APGAR at
5 and 10 min, and incidence of other risk factors that
could affect neurodevelopment (e.g., sepsis, intracranial
haemorrhage, bronchopulmonary dysplasia). The study
aimed to provide similar nutrition to all preterm infants
in the two groups during this period. The two study
groups were also compared to a breast milk-only group.
However, the two study formulas differed not only in the
proportion of omega 6 and omega 3 LCPUFAs, but also
in the total amount of LCPUFAs. It cannot be excluded
that the better performance of infants fed with formula
A could be attributable to the total quantity (and not the
ratio) of LCPUFAs.
International groups have published recommendations
for the optimal levels of ω-3 and ω-6 during the first three
years of life, with recommended ω-3 supplementation
ranging from 0.6 % to 2 % of daily energy requirements
compared with 5 %-10 % of ω-6 (almost a 10-fold
difference) [24] The European Society for Paediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Committee on Nutrition suggests that the daily intake for
a preterm infant include the following: DHA, 12 to
30 mg/kg (≈0.2 %-0.5 % of all fatty acids) and AA, 18 to
42 mg/kg (≈0.3 %-0.7 % of all fatty acids) [25].
Multiple studies have confirmed the importance of
PUFAs in preterm infants’ mental development and have
reported that preterm infants fed with supplemental PUFAs
Table 3 Comparison of Brunet Lézine score in very preterm infants in group A, B, and control
24 months
Brunet-Lézine score
ω-6/ω-3 = 2
Group A n = 24
ω-6/ω-3 = 1
Group B n = 21
p value Control group
n = 25
ω-6/ω-3 = 2
Group A n = 24
p value Control
group n = 25
ω-6/ω-3 = 1
Group B n = 21
p value
Mean (SD) 99.9 (9) 90.8 (11) 0.028 100.5 (7) 99.9 (9) ns 100.5 (7) 90.8 (11) 0.007
<85 1 (4.2 %) 6 (28.6 %) 0.039 1 (4 %) 1 (4.2 %) ns 1 (4 %) 6 (28.6 %) 0.036
≥85 23 (95.8 %) 15 (71.4 %) 24 (96 %) 23 (95.8 %) 24 (96 %) 15 (71.4 %)
Data are presented as number (ratio) or mean (SD). Significant differences between groups (p <0.05, Chi-square test for comparing ratios, Wilcoxon test for
comparing scores)
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Table 4 Comparison of fatty acids in plasma in very preterm infants between two sample groups
Concentration in plasma (% of
weight of total lipids)
Birth 3 months 6 months 12 months
ω-6/ω-3 = 2 ω-6/ω-3 = 1 ω-6/ω-3 = 2 ω-6/ω-3 = 1 ω-6/ω-3 = 2 ω-6/ω-3 = 1 ω-6/ω-3 = 2 ω-6/ω-3 = 1
Group A (n = 24) Group A (n = 20) Group A (n = 22) Group B (n = 18) Group A (n = 22) Group B (n = 18) Group A (n = 24) Group B (n = 18)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Saturated fatty acids
C12:0 1.38 (0.88) 1.02 (0.55) 2.89 (1.75) 1.17 (0.45)* 5.05 (1.85) 3.62 (1.51) 3.72 (1.08) 4.35 (1.19)
C14:0 1.40 (0.52) 1.34 (0.52) 1,90 (0.65) 1.17 (0.15)* 2.03 (0.36) 1.88 (0.35) 1.74 (0.31) 1.94 (0.38)
C15:0 0.63 (0.48) 0.48 (0.28) 0.43 (0.21) 0.49 (0.22) 0.46 (0.14) 0.42 (0.17) 0.45 (0.25) 0.37 (0.14)
C16:0 21.78 (2.17) 23.70 (3.44) 19.86 (2.78) 20.33 (1.08) 19.94 (1.05) 21.01 (0.77) 19.77 (1.00) 19.59 (0.85)
C17:0 0.51 (0.14) 0.48 (0.14) 0.46 (0.11) 0.45 (0.11) 0.35 (0.11) 0.36 (0.08) 0.38 (0.11) 0.34 (0.08)
C18:0 8.33 (1.33) 8.24 (1.43) 8.50 (1.12) 8.24 (0,79) 7.25 (0.86) 7.39 (0.70) 7.31 (0.94) 6.73 (0.89)
C20:0 0.27 (0.10) 0.23 (0.13) 0.20 (0.08) 0.28 (0.05)* 0.14 (0.05) 0.18 (0.06) 0.21 (0.04) 0.24 (0.04)
C22:0 0.90 (0.34) 1.08 (0.35) 0.70 (0.46) 0.58 (0.07) 0.60 (0.14) 0.56 (0.05) 0.55 (0.09) 0.54 (0.09)
C23:0 0.04 (0.03) 0.03 (0.01) 0.03 (0.02) 0.03 (0.03) 0.01 (0.01) 0.02 (0.01) 0.01 (0.01) 0.01 (0.00)
C24:0 0.44 (0.13) 0.40 (0.12) 0.34 (0.10) 0.38 (0.06) 0.42 (0.16) 0.39 (0.08) 0.45 (0.13) 0.39 (0.10)
C26:0 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.01) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
SFA 35.69 (4.24) 36.99 (4.78) 35.31 (3.49) 33.13 (1.86) 36.26 (1.59) 35.68 (1.40) 34.58 (1.25) 34.50 (1.49)
Monounsaturated fatty acids
C14:1ω5 0.34 (0.23) 0.20 (0.07) 0.35 (0.23) 0.19 (0.17) 0.17 (0.11) 0.17 (0.09) 0.12 (0.04) 0.09 (0.01)
C16:1ω7 3.39 (1.67) 4.64 (2.48) 1.86 (2.48) 1.02 (0.41) 0.77 (0.22) 1.03 (0.40) 1.10 (0.30) 0.98 (0.34)
C18:1ω9 (t) 0.24 (0.13) 0.23 (0.11) 0.27 (0.13) 0.24 (0.05) 0.18 (0.06) 0.19 (0.05) 0.18 (0.04) 0.17 (0.05)
C18:1ω9 (c) 24.78 (2.99) 26.30 (3.36) 25.39 (2.17) 26.50 (2.63) 22.97 (1.90) 24.62 (2.02) 22.03 (2.13) 25.06 (2.52)*
C18:1ω7 0.59 (1.02) 0.49 (0.81) 0.31 (0.62) 0.14 (0.09) 0.16 (0.19) 0.36 (0.50) 0.11 (0.03) 0.14 (0.11)
C20:1ω9 0.11 (0.25) 0.05 (0.01) 0.05 (0.04) 0.07 (0.03)* 0.05 0.02) 0.05 (0.01) 0.05 (0.01) 0.05 (0.01)
C22:1ω9 0.07 (0.03) 0.08 (0.03) 0.05 (0.02) 0.06 (0.02) 0.05 (0.02) 0.05 (0.02) 0.04 (0.02) 0.05 (0.01)
C24:1ω9 1.08 (0.33) 1.26 (0.36) 0.90 (0.34) 0.96 (0.41) 0.70 (0.17) 0.87 (0.19)* 0.77 (0.18) 0.88 (0.18)
MUFA 30.60 (3.77) 33.25 (4.89) 29.18 (3.74) 29.17 (2.53) 25.04 (1.86) 27.35 (1.71)* 24.40 (1.90) 27.42 (2.53)*
Polyunsaturated fatty acids
C18:2ω6 (t) 0.12 (0.07) 0.11 (0.05) 0.12 (0.05) 0.13 (0.02) 0.15 (0.13) 0.11 (0.04) 0.12 (0.04) 0.10 (0.01)*
C18:2ω6 (c) 19.89 (8.41) 16.57 (9.27) 23.36 (5.56) 26.43 (2.18) 26.75 (1.99) 26.91 (1.63) 28.22 (1.74) 27.68 (1.66)
C18:3ω6 1.36 (0.92) 1.42 (0.91) 0.91 (0.63) 1.36 (0.77) 1.06 (0.62) 1.64 (0.74) 1.48 (0.73) 1.69 (0.57)
C18:3ω3 0.98 (1.07) 0.84 (0.98) 0.82 (0.28) 0.95 (0.18) 0.69 (0.16) 0.84 (0.08)* 0.71 (0.17) 0.91 (0.13)*
C20:2ω6 0.10 (0.06) 0.08 (0.04) 0.09 (0.08) 0.10 (0.05) 0.08 (0.04) 0.12 (0.09) 0.08 (0.01) 0.07 (0.01)
C20:3ω9 0.10 (0.03) 0.10 (0.04) 0.09 (0.03) 0.09 (0.03) 0.06 (0.02) 0.05 (0.03) 0.00 (0.00) 0.00 (0.01)
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Table 4 Comparison of fatty acids in plasma in very preterm infants between two sample groups (Continued)
C20:3ω6 1.45 (0.39) 1.57 (0.55) 1.14 (0.29) 1.44 (0.42)* 0.69 (0.20) 0.82 (0.27) 0.87 (0.18) 0.90 (0.18)
C20:4ω6 7.20 (1.75) 6.80 (1.57) 6.56 (1.29) 4.77 (1.09)* 6.74 (0.88) 4.22 (1.16)* 6.95 (1.55) 4.55 (0.78)*
C20:5ω3 0.16 (0.13) 0.10 (0.14) 0.12 (0.10) 0.11 (0.10) 0.06 (0.07) 0.06 (0.07) 0.02 (0.01) 0.02 (0.01)
C22:4ω6 0,37 (0.12) 0.37 (0.07) 0.29 (0.07) 0.28 (0.05) 0.28 (0.06) 0.29 (0.05) 0.38 (0.07) 0.31 (0.08)
C22:5ω6 0.05 (0.04) 0.07 (0.05) 0.07 (0.10) 0.05 (0.02) 0.04 (0.01) 0.04 (0.02) 0.04 (0.01) 0.04 (0.01)
C22:5ω3 0.05 (0.03) 0.05 (0.03) 0.04 (0.02) 0.05 (0.02)* 0.05 (0.02) 0.05 (0.02) 0.06 (0.02) 0.06 (0.02)
C22:6ω3 1.89 (0.65) 1.70 (0.47) 1.90 (0.37) 1.93 (0.25) 2.05 (0.37) 1.66 (0.29)* 2.02 (0.51) 1.67 (0.38)
Total ω6 30.54 (6.73) 26.97 (8.12) 32.55 (5.53) 34.56 (1.80) 36.76 (2.54) 34.15 (1.61)* 38.14 (2.21) 35.34 (2.43)*
Total ω3 3.07 (0.88) 2.68 (0.79) 2.87 (0.50) 3.04 (0.29) 2.84 (0.33) 2.62 (0.28)* 2.81 (0.42) 2.67 (0.39)
ω-6/ω-3 10.41 (2.91) 10.30 (2.25) 11.5 (1.9) 11.4 (1.2) 12.7 (1.7) 13.2 (1.2) 13.9 (2.7) 13.5 (2.5)
PUFA 33.71 (7.27) 29.75 (8.77) 35.51 (5.78) 37.69 (1.87) 38.69 (2.52) 36.82 (1.81)* 41.02 (2.09) 38.08 (2.32)*
Data are presented as mean (SD). *Significant differences between groups (p < 0.05, Wilcoxon test)
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Table 5 Comparison of somatic growth and evoked potentials between two sample groups
Comparison of somatic growth and
evoked potentials between two
groups
ω-6/ω-3 = 2 Group A ω-6/ω-3 = 1 Group B p
valuen = 24 (12 M and 12 F) n = 21 (10 M and 11 F)
Mean (SD) Mean (SD)
Weight (g) At birth M 1460 (355) 1254 (362) ns
At birth F 1287 (228) 1154 (176) ns
At 12 months M 9233 (989) 9276 (2053) ns
At 12 months F 8368 (1408) 7040 (711) ns
At 24 months M 12192 (1218) 12295 (1878) ns
At 24 months F 11038 (2503) 9979 (956) ns
Length (cm) At birth M 40.6 (3.6) 39.1 (2.8) ns
At birth F 38.4 (1.2) 36,4 (1.7) ns
At 12 months M 74.1 (2.7) 73.6 (5.8) ns
At 12 months F 69.8 (3.1) 68.4 (0.9) ns
At 24 months M 86.1 (2.7) 84.9 (4.1) ns
At 24 months F 82.9 (3.1) 81.7 (2,9) ns
Head circumference (cm) At birth M 28.4 (1.7) 27.5 (2.1) ns
At birth F 27.6 (1.9) 27.1 (1.8) ns
At 12 months M 45.7 (1) 45.9 (1.5) ns
At 12 months F 45.3 (1.7) 45.1 (1.1) ns
At 24 months M 48.6 (1) 48.4 (1.8) ns
At 24 months F 47.9 (1.7) 48 (0.8) ns
% normal % normal
Visual-evoked potentials At 6 months 92 % 81 % ns
At 12 months 96 % 86 % ns
Brainstem auditory-evoked potentials At 6 months 79 % 86 % ns
At 12 months 83 % 90 % ns
cm centimeter, g gram, M male, F female, ns indicating no significant differences between groups (p < 0.05, Wilcoxon test for growth, Chi-square test for potentials)
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(especially DHA) showed improved brain development.
However, none of these trials clearly recommended an ω-6
to ω-3 ratio [11, 12, 26].
A review of the scientific literature showed that the
AA/DHA ratio in formula milk (often 1/1) is different
from the AA/DHA ratio in breast milk. In a review of 65
studies involving 2474 women, the mean concentration
of DHA in breast milk was 0.32 % (range: 0.06 %–1.4 %)
and that of AA was 0.47 % (range: 0.24 % –1.0 %) [27].
In a study on FA composition of mothers’ milk at 3, 7,
and 28 days post-partum in term and preterm infants,
the ratio of AA/DHA was approximately 3/1 and 2/1, re-
spectively, with DHA levels between 0.5 %-1.0 %, and
AA levels between 1.3 %-2.6 % [28]. Also, in one investi-
gation conducted in nine countries concerning breast
milk for term neonates, 7 countries reported an AA/
DHA ratio greater than 1/1 and only 2 countries re-
ported a ratio of less than 1/1 (range, from 0.51/1 in
Japan to 3.16/1 in the USA) [29]. In a new study of term
infants in the USA, the AA/DHA ratio in breast milk
was 2.64/1 at birth and 2.81/1 at 6 weeks [8].
Interestingly, despite having different formula ratios of
AA/DHA, the same quantity of DHA, and almost the
same proportion of mixed-fed children (breast-fed with
formula) in groups A and B, there was almost no differ-
ence between the two groups in plasma ω-6/ω-3 ratio
and group A had higher DHA levels than group B at
6 months. This could have been because α-Linolenic
acid and Linoleic acid compete for the same enzyme
pathways to form DHA and AA, respectively [30], and
since group A had higher AA supplementation, the in-
ternal balance of LCPUFA synthesis could have shifted
towards DHA. In addition, plasma omega-6/omega-3 ra-
tios were not expected to be similar, and this result could
have been because omega-6 and omega-3 have many com-
ponents besides AA and DHA. The balance of omega-6
and omega-3 is highly complex, and our trial is the first in
addressing AA, as previous trials have focused on DHA
and overlooked AA. Therefore, further studies are required
to understand the complex relationship between omega-6
and omega-3. However, plasma PUFAs were higher in
group A than in group B. This means that the increased
quantity of AA in the milk given did not affect the balance
between ω-6 and ω-3. This balance is considered very im-
portant in human health and growth [9].
A recent review showed that LC-PUFA supplementa-
tion during pregnancy was associated with modest
increases in birth size in both low-income and high-
income populations. However, postnatal supplementa-
tion with LC-PUFAs did not influence infant growth
[31]. Throughout our study, anthropometric growth was
measured during the first two years of life in groups A
and B, and weight, height, and head circumference
growth were similar in the two groups. Therefore, these
results suggest that higher formula levels of omega-6 do
not affect anthropometric growth.
The VEP results of group A and group B were com-
pared, showing no major differences in visual function, a
result that supports the unique importance of DHA in vis-
ual pathway maturation in preterm infants. Underscoring
this, DHA levels have been shown to reach 30 %-40 % of
total fatty acids in rod photoreceptor outer segments of
the human retina [32] and the two formula groups re-
ceived the same quantity of DHA. This result was despite
of the different plasma DHA values at 6 months.
Theoretically, the auditory tracts are neural fibres, and
LC-FUFAs are thought to be important in their develop-
ment and maturation. However, no studies were found
to support this hypothesis. Paradoxically, one study
showed no effect of LC-PUFA on auditory brain-stem
evoked responses [33]. Due to the above data, no im-
portant differences were anticipated between the two
groups in terms of auditory function, despite one group
having double the quantity of AA.
All mothers were from the same geographical area,
were of the same ethnicity and religion, and had similar
dietary habits. There are several studies on the omega-6/
omega-3 ratio in breast milk confirming minimal differ-
ences in this ratio in the same geographical region, and
marked differences only between distant parts of the
world, because of distinct dietary habits [27, 29]. There-
fore, in this study, the breast milk omega-6/omega-3 ra-
tio was not measured, as it was understood that it would
contain a similar ratio, and that the significant difference
in the omega-6/omega-3 ratio was between the supple-
mental formulas only. Also, the number of mixed-fed
babies decreased significantly after the first month of life
(from the first month to the third month, from 54 % to
21 % in group A and from 48 % to 24 % in group B).
There was a variety of factors that were difficult to con-
trol, for example the socio-economic status and the edu-
cational level of the mother [34, 35]. These factors could
have played an important role in neurodevelopment and
cognitive function. Finally, the relatively small sample sizes
(as a result of more children than expected being lost to
follow-up) could be another limitation of this trial.
In conclusion, the improved LCPUFA plasma concen-
trations and psychomotor development in very preterm
infants despite the same formula quantity of DHA could
have been due to the double mount ratio of AA to DHA
or the higher total quantity of LCPUFAs. Nevertheless,
further studies are required to support the benefits of a
balanced AA/DHA ratio (more AA) in preterm infant
supplementation.
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